BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36135081)

  • 1. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
    Chilamakuri R; Agarwal S
    Curr Oncol; 2022 Sep; 29(9):6508-6522. PubMed ID: 36135081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA SNHG16 regulates cell behaviors through miR-542-3p/HNF4α axis via RAS/RAF/MEK/ERK signaling pathway in pediatric neuroblastoma cells.
    Deng D; Yang S; Wang X
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32412051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NeiyiKangfu tablets control the progression of endometriosis through inhibiting RAF/MEK/ERK signal pathway by targeting RKIP.
    Wen Y; Fan L; Pang L; Zhao T; Li R; Zhang Y; Zhang L; Yang W
    Gynecol Endocrinol; 2022 Dec; 38(12):1136-1146. PubMed ID: 36592742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
    Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
    J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
    Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
    Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
    Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
    Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.
    Xie G; Wu H; Cai W; Chen M; Huang W; Yan W; Chang Y
    FEBS Open Bio; 2019 Mar; 9(3):490-497. PubMed ID: 30868057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
    Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
    Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling.
    Sandoval JA; Eppstein AC; Hoelz DJ; Klein PJ; Linebarger JH; Turner KE; Rescorla FJ; Hickey RJ; Malkas LH; Schmidt CM
    J Surg Res; 2006 Jul; 134(1):61-7. PubMed ID: 16650873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
    Romerio F; Riva A; Zella D
    Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Agonist of Adenosine A1 Receptor Induced Desensitization of delta Opioid receptor-mediated Raf-1/MEK/ERK Signaling by Feedback Phosphorylation of Raf-1-Ser289/296/301.
    Xu C; Cheng Y; Han M; Tao Y; Liu JG
    Neurochem Res; 2023 May; 48(5):1531-1542. PubMed ID: 36525124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.
    Zhou J; Tu D; Peng R; Tang Y; Deng Q; Su B; Wang S; Tang H; Jin S; Jiang G; Wang Q; Jin X; Zhang C; Cao J; Bai D
    Cell Commun Signal; 2023 Aug; 21(1):224. PubMed ID: 37626338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
    Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
    J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.